Intervention description {11a}
PERIPHERAL NEUROPATHY
The intervention for this trial is oral gabapentin hydrochloride 300 mg. The capsules will be manufactured and packed into capped plastic containers by Intas pharmaceuticals.Participants will be provided with four containers of 40 capsules each to suffice for oral administration of up to six cycles of paclitaxel and further 3 weeks (18 weeks). The participant will take one capsule (gabapentin or placebo) at nighttime until 3 weeks after the last cycle of paclitaxel or development of NCI CTCAE v5.0 peripheral neuropathy (grade 2 or higher), whichever is earlier.